Candel therapeutics receives ema orphan designation for can-2409 for the treatment of pancreatic cancer

Needham, mass., july 24, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the european medicines agency (ema) has granted orphan designation for can-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. this designation complements can-2409's existing u.s. food and drug administration (fda) orphan drug designation and fda fast track designation for the treatment of pancreatic ductal adenocarcinoma (pdac) awarded to can-2409 in april 2024 and december 2023, respectively, and underscores the significant unmet medical need in this disease beyond the u.s.
CADL Ratings Summary
CADL Quant Ranking